Compare ENR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | RCKT |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 534.2M |
| IPO Year | 2015 | N/A |
| Metric | ENR | RCKT |
|---|---|---|
| Price | $17.08 | $4.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $25.00 | ★ $29.65 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.18% | N/A |
| EPS Growth | ★ 538.46 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $1.07 | $97.68 |
| P/E Ratio | $5.05 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $16.38 | $2.19 |
| 52 Week High | $30.29 | $8.80 |
| Indicator | ENR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 32.54 | 48.79 |
| Support Level | $16.76 | $4.16 |
| Resistance Level | $20.92 | $4.51 |
| Average True Range (ATR) | 0.71 | 0.34 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 15.93 | 16.93 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.